[HTML][HTML] Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label …
E Wajs, L Aluisio, R Holder, EJ Daly… - The Journal of clinical …, 2020 - psychiatrist.com
Objective: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …
Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double …
M Fedgchin, M Trivedi, EJ Daly… - International Journal …, 2019 - academic.oup.com
Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …
treatment with multiple antidepressants and are considered to have treatment-resistant …
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a …
N Takahashi, A Yamada, A Shiraishi, H Shimizu… - BMC psychiatry, 2021 - Springer
Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral
antidepressants (ADs) is approved in the European Union, United States, and other markets …
antidepressants (ADs) is approved in the European Union, United States, and other markets …
Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized …
V Popova, EJ Daly, M Trivedi… - American Journal of …, 2019 - Am Psychiatric Assoc
Objective: About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants. This study compared the efficacy and safety of …
treatment with multiple antidepressants. This study compared the efficacy and safety of …
Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial
EJ Daly, MH Trivedi, A Janik, H Li, Y Zhang, X Li… - JAMA …, 2019 - jamanetwork.com
Importance Controlled studies have shown short-term efficacy of esketamine for treatment-
resistant depression (TRD), but long-term effects remain to be established. Objective To …
resistant depression (TRD), but long-term effects remain to be established. Objective To …
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
N Zaki, L Chen, R Lane, T Doherty… - …, 2023 - nature.com
Patients with treatment-resistant depression (TRD) have higher rates of relapse and
pronounced decreases in daily functioning and health-related quality of life compared to …
pronounced decreases in daily functioning and health-related quality of life compared to …
Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme
L Samalin, M Rothärmel, L Mekaoui… - … Journal of Psychiatry …, 2022 - Taylor & Francis
Objective To present the first real-world data of patients with treatment-resistant depression
(TRD) treated with esketamine through a French cohort Temporary Authorisation for Use …
(TRD) treated with esketamine through a French cohort Temporary Authorisation for Use …
Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial
EJ Daly, JB Singh, M Fedgchin, K Cooper, P Lim… - JAMA …, 2018 - jamanetwork.com
Importance Approximately one-third of patients with major depressive disorder (MDD) do not
respond to available antidepressants. Objective To assess the efficacy, safety, and dose …
respond to available antidepressants. Objective To assess the efficacy, safety, and dose …
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge …
S Kasper, WJ Cubała, A Fagiolini… - The World Journal of …, 2021 - Taylor & Francis
Objectives Despite the available therapies for treatment-resistant depression (TRD), there
are a limited number that are evidence-based and effective in this hard-to-treat population …
are a limited number that are evidence-based and effective in this hard-to-treat population …
Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
MS Salahudeen, CM Wright… - … advances in drug …, 2020 - journals.sagepub.com
This narrative review aims to provide an overview of the current literature on the
pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of …
pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of …